Onconetix, Inc.
ONCOHealthcare|Biotechnology|US
$6.95
+1.46 (+26.59%)
DCF Value
$13.80
Tangible Book / Share
$17.17
Cash / Share
$26.50
Financials
Financial Snapshot
Market Cap
$2.5M
Enterprise Value
-$3.3M
Revenue (TTM)
$645.8K
Net Income (TTM)
-$10.2M
Cash & Investments
$5.9M
Net Cash
$5.8M
Free Cash Flow (TTM)
-$10.3M
Operating CF (TTM)
-$10.3M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$5.9M
Quarterly Burn
$2.6M
Monthly Burn
$859.0K
Est. Runway
~2.3 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $6.1M | $4.3M | $1.9M | $25.8M | $4.6M | $646.5K | $5.2M | $5.9M | |
| Operating Cash Flow | -$825.1K | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M | -$10.3M | |
| Free Cash Flow | -$829.6K | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M | -$10.3M | |
| Capital Expenditure | -$4.5K | -$11.8K | -$1.9K | -$9.3K | -$55.0K | -$28.5K | $0.00 | $3.00 | |
| Financing Cash Flow | $6.9M | $0.00 | -$334.2K | $32.5M | $1.0M | $6.7M | $14.5M | $15.6M |
R&D Spending
R&D (TTM)
$75.3K
R&D Intensity
11.7%
R&D Growth vs Prior
—
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $58.5K | $2.5M | $815.4K | $645.8K | |
| R&D Expense | $60.2K | $524.9K | $1.3M | $4.1M | $1.9M | $154.4K | -$66.1K | $75.3K | |
| R&D % of Revenue | — | — | — | — | 3334.3% | 6.1% | -8.1% | 11.7% | |
| SG&A | $819.5K | $1.1M | $2.1M | $9.4M | $14.8M | $11.2M | $7.0M | $8.1M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $58.5K | $2.5M | $815.4K | $645.8K | |
| Cost of Revenue | $573.00 | $3.1K | $4.9K | $6.8K | $1.2M | $1.5M | $182.5K | $126.6K | |
| Gross Profit | -$573.00 | -$3.1K | -$4.9K | -$6.8K | -$1.1M | $1.1M | $632.9K | $519.2K | |
| R&D | $60.2K | $524.9K | $1.3M | $4.1M | $1.9M | $154.4K | -$66.1K | $75.3K | |
| SG&A | $819.5K | $1.1M | $2.1M | $9.4M | $14.8M | $11.2M | $7.0M | $8.1M | |
| Operating Income | -$880.2K | -$1.6M | -$3.4M | -$13.5M | -$36.0M | -$56.5M | -$6.3M | -$8.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $671.6K | $1.4M | $751.0K | $310.9K | |
| Pretax Income | -$821.9K | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$59.7M | -$14.0M | -$10.2M | |
| Net Income | -$821.9K | -$1.6M | -$3.4M | -$13.4M | -$37.4M | -$58.7M | -$14.0M | -$10.2M | |
| EPS (Diluted) | -0.21 | -0.40 | -0.89 | -3.11 | -250.29 | -5209.29 | -47.30 | -87.36 | |
| EBITDA | -$821.3K | -$1.6M | -$3.4M | -$13.4M | -$36.7M | -$57.6M | -$13.3M | -$9.9M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.33 | 0.22 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.1M | $4.3M | $1.9M | $25.8M | $4.6M | $646.5K | $5.2M | $5.9M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $6.1M | $4.6M | $3.1M | $26.3M | $5.8M | $950.3K | $6.1M | $6.5M | |
| Total Assets | $6.1M | $4.8M | $3.1M | $26.3M | $87.5M | $28.2M | $24.9M | $16.4M | |
| Total Current Liabilities | $75.8K | $68.7K | $1.6M | $3.9M | $17.2M | $18.3M | $9.1M | $2.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $118.9K | $0.00 | $24.4K | $12.3K | |
| Total Liabilities | $82.6K | $78.3K | $1.6M | $3.9M | $86.1M | $18.6M | $9.2M | $3.0M | |
| Stockholders' Equity | $6.0M | $4.7M | $1.4M | $22.4M | -$5.6M | $9.6M | $15.8M | $13.5M | |
| Retained Earnings | -$939.9K | -$2.5M | -$6.0M | -$19.4M | -$56.8M | -$115.7M | -$131.2M | -$138.3M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$825.1K | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M | -$10.3M | |
| Capital Expenditure | -$4.5K | -$11.8K | -$1.9K | -$9.3K | -$55.0K | -$28.5K | $0.00 | $3.00 | |
| Free Cash Flow | -$829.6K | -$1.7M | -$2.0M | -$8.7M | -$13.6M | -$10.5M | -$9.7M | -$10.3M | |
| Investing Cash Flow | -$4.5K | -$11.8K | -$1.9K | -$32.7K | -$8.6M | -$28.5K | $0.00 | $0.00 | |
| Financing Cash Flow | $6.9M | $0.00 | -$334.2K | $32.5M | $1.0M | $6.7M | $14.5M | $15.6M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $34.9M | $0.00 | $685.3K | $20.2M | $20.2M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$566.8K | -$59.0K | -$718.00 | $0.00 | $0.00 | |
| Net Debt Issuance | -$54.6K | $0.00 | $0.00 | $0.00 | -$1.0M | $3.7M | -$5.8M | -$4.6M | |
| Stock Based Comp. | $3.3K | $334.8K | $130.1K | $2.0M | $329.8K | $438.7K | $74.3K | $43.7K | |
| Net Change in Cash | $6.1M | -$1.7M | -$2.4M | $23.8M | -$21.2M | -$3.9M | $4.6M | $5.7M |
Dilution Tracker
Shares outstanding grew 28764.7% over 5 years — significant dilution
Shares Outstanding
0M
5-Year Share Growth
+28764.7%
Stock Issuance (TTM)
$20.2M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.33 | 0.22 | |
| Change vs Prior % | — | 0.0% | 0.0% | 11.1% | 39.4% | 542.0% | 2803.1% | -31.7% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $34.9M | $0.00 | $685.3K | $20.2M | $20.2M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$566.8K | -$59.0K | -$718.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.3K | $334.8K | $130.1K | $2.0M | $329.8K | $438.7K | $74.3K | $43.7K |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | -1927.9% | 41.8% | 77.6% | 80.4% | |
| Operating Margin % | — | — | — | — | -61634.5% | -2238.0% | -778.2% | -1265.5% | |
| Net Margin % | — | — | — | — | -63986.5% | -2325.2% | -1721.0% | -1578.8% | |
| EBITDA Margin % | — | — | — | — | -62784.1% | -2281.9% | -1626.9% | -1528.3% | |
| FCF Margin % | — | — | — | — | -23323.5% | -416.9% | -1187.0% | -1596.1% | |
| ROE % | -13.7% | -33.8% | -236.2% | -59.9% | 667.8% | -610.7% | -89.0% | -92.0% | |
| ROA % | -13.5% | -33.2% | -110.8% | -51.0% | -42.7% | -208.3% | -56.3% | -62.1% | |
| ROIC % | -14.7% | -34.2% | -236.2% | -60.2% | -45.0% | -287.0% | -40.1% | -59.8% | |
| R&D / Revenue % | — | — | — | — | 3334.3% | 6.1% | -8.1% | 11.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4217.3% | -67.7% | |
| Gross Profit | 0.0% | -433.3% | -60.0% | -38.1% | -16593.8% | 193.6% | -40.0% | |
| Operating Income | 0.0% | -84.3% | -110.7% | -294.5% | -167.3% | -56.8% | 88.8% | |
| Net Income | 0.0% | -94.6% | -113.7% | -292.7% | -178.8% | -56.9% | 76.1% | |
| EPS (Diluted) | 0.0% | -88.2% | -121.4% | -251.6% | -7936.7% | -1981.3% | 99.1% | |
| Operating Cash Flow | 0.0% | -109.7% | -18.2% | -324.4% | -56.5% | 22.7% | 7.8% | |
| Free Cash Flow | 0.0% | -110.0% | -17.5% | -324.4% | -57.0% | 22.8% | 8.0% | |
| R&D Expense | 0.0% | 772.3% | 152.4% | 211.7% | -52.8% | -92.1% | -142.8% | |
| SG&A Expense | 0.0% | 33.9% | 90.7% | 346.9% | 57.9% | -24.0% | -37.3% | |
| Total Assets | 0.0% | -20.9% | -35.9% | 752.9% | 232.6% | -67.8% | -11.5% | |
| Book Value / Share | 0.0% | -21.1% | -69.4% | 1293.3% | -95.5% | 6.6% | -94.3% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -4.4% | -99.5% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 11.1% | 39.4% | 542.0% | 2803.1% |
Valuation
P/E (TTM)At Loss
P/S3.86
10Y Low / Med / High119.92 / 313.95 / 10138.59
P/B0.12
10Y Low / Med / High16.24 / 18496.35 / 76697.24
EV/EBITDA0.33
EV/Revenue-5.05
10Y Low / Med / High123.41 / 307.61 / 10229.78
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$13.80
Tangible Book / Share
$17.17
Net Current Assets / Share
$9.93
Graham Net-Net
$13.78
Cash / Share
$26.50
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -459045698.92 | -243950000.00 | -110170967.74 | -600458.72 | -1344.86 | -5.14 | -16.49 | -0.08 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 10138.59 | 119.92 | 313.95 | 3.86 | |
| P/B Ratio | 18496.35 | 23437.65 | 76697.24 | 105.49 | -105.81 | 31.50 | 16.24 | 0.12 | |
| EV/EBITDA | -135074.56 | -69496.03 | -32512.34 | -174.16 | -16.29 | -5.41 | -18.91 | 0.33 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 10229.78 | 123.41 | 307.61 | -5.05 |
Analyst Estimates & Quality
Altman Z-Score
-12.97
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 |
|---|---|---|
| Revenue | $881.2K | $952.4K |
| Net Income | -$65.84B | -$70.30B |
| EPS | $-200600.00 | $-214200.00 |
| # Analysts (EPS) | 1 | 1 |
Revenue Segments
By Product
| Segment | 2025 |
|---|---|
| License | $0.60 |
By Geography
| Segment | 2023 | 2024 | 2025 |
|---|---|---|---|
| SWITZERLAND | $58.5K | — | — |
| European Union | — | $2.4M | $796.6K |
| UNITED STATES | — | $63.1K | — |